Meridian Bioscience Fiscal Q4, FY15 Revenues Show Modest Growth | GenomeWeb

NEW YORK (GenomeWeb) – Meridian Bioscience today reported its fiscal fourth quarter and fiscal year revenues grew 1 percent and 3 percent, respectively.

For the quarter ended Sept. 30, the Cincinnati, Ohio-based molecular diagnostics manufacturer saw fourth quarter revenue increase from $46.7 million to $47.1 million, edging out analysts' consensus estimate of $46.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.